Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Esperion Therapeutics Inc.’s stock clocked out at $1.96, down -0.51% from its previous closing price of $1.97. In other words, the price has decreased by -$0.51 from its previous closing price. On the day, 3.6 million shares were traded. ESPR stock price reached its highest trading level at $2.03 during the session, while it also had its lowest trading level at $1.95.
Ratios:
To gain a deeper understanding of ESPR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.49 and its Current Ratio is at 1.97.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 17 ’24 when Warren Eric sold 108 shares for $2.59 per share. The transaction valued at 279 led to the insider holds 165,478 shares of the business.
Foody Joanne M. sold 917 shares of ESPR for $2,383 on Jul 17 ’24. The Chief Medical Officer now owns 272,862 shares after completing the transaction at $2.60 per share. On Jun 18 ’24, another insider, Foody Joanne M., who serves as the Chief Medical Officer of the company, sold 3,285 shares for $2.87 each. As a result, the insider received 9,418 and left with 273,779 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 384600992 and an Enterprise Value of 464431392. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.34. Its current Enterprise Value per Revenue stands at 1.672 whereas that against EBITDA is 93.072.
Stock Price History:
Over the past 52 weeks, ESPR has reached a high of $3.40, while it has fallen to a 52-week low of $0.70. The 50-Day Moving Average of the stock is -17.26%, while the 200-Day Moving Average is calculated to be -10.12%.
Shares Statistics:
It appears that ESPR traded 7.44M shares on average per day over the past three months and 5533690 shares per day over the past ten days. A total of 189.46M shares are outstanding, with a floating share count of 187.38M. Insiders hold about 8.30% of the company’s shares, while institutions hold 75.01% stake in the company. Shares short for ESPR as of 1722384000 were 38135175 with a Short Ratio of 5.13, compared to 1719532800 on 23549800. Therefore, it implies a Short% of Shares Outstanding of 38135175 and a Short% of Float of 20.18.
Earnings Estimates
The stock of Esperion Therapeutics Inc. (ESPR) is currently being evaluated by 7.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.07, with high estimates of $0.38 and low estimates of -$0.22.
Analysts are recommending an EPS of between $0.31 and -$0.45 for the fiscal current year, implying an average EPS of -$0.18. EPS for the following year is $0.2, with 6.0 analysts recommending between $1.29 and -$0.36.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $63.18M. There is a high estimate of $80.9M for the next quarter, whereas the lowest estimate is $52.1M.
A total of 7 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $462.2M, while the lowest revenue estimate was $307.1M, resulting in an average revenue estimate of $344.69M. In the same quarter a year ago, actual revenue was $116.33MBased on 6 analysts’ estimates, the company’s revenue will be $428.54M in the next fiscal year. The high estimate is $664.8M and the low estimate is $271.8M.
